Application for quotation of +securities
Update Summary
For personal use only
Entity name
AMPLIA THERAPEUTICS LIMITED
Announcement Type
Update to previous announcement
Date of this announcement
Monday December 20, 2021
Reason for the update
To confrim shareholder approval of Resolution 2 at EGM held on 17 December 2021 and actual number (due to rounding) of ATXO options issued to Placement participants.
Refer to next page for full details of the announcement
Application for quotation of +securities | 1 / 7 |
Application for quotation of +securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of entity
AMPLIA THERAPEUTICS LIMITED
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2 | Registered number type | Registration number |
ABN | 16165160841 | |
1.3 | ASX issuer code | |
ATX |
1.4 The announcement is
Update/amendment to previous announcement
1.4a Reason for update to a previous announcement
To confrim shareholder approval of Resolution 2 at EGM held on 17 December 2021 and actual number (due to rounding) of ATXO options issued to Placement participants.
1.4b Date of previous announcement to this update
15/12/2021
1.5 Date of this announcement
20/12/2021
Application for quotation of +securities | 2 / 7 |
Application for quotation of +securities
Part 2 - Type of Issue
2.1 The +securities to be quoted are:
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B
For personal use only
Previous Appendix 3B details: | ||
Announcement Date and | Announcement Title | Selected Appendix 3B to submit quotation |
Time | request | |
08-Nov-2021 09:54 | New - Proposed issue of securities - | |
A standard +pro rata issue (non-renounceable) | ||
ATX | ||
2.3a.2 Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?
No
Application for quotation of +securities | 3 / 7 |
Application for quotation of +securities
Part 3A - number and type of +securities to be quoted where issue has previously been notified to ASX in an Appendix 3B
Corporate Action Component Detail | ||
only | ASX +security code and description | |
ATX : ORDINARY FULLY PAID | ||
Issue date | ||
use | 14/12/2021 | |
Distribution Schedule | ||
Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - | ||
including the number of recipients and the total percentage of the new +securities held by the recipients in each | ||
category. |
personalFor | Total percentage of +securities held | |||
Number of +securities held | Number of holders | For example, to enter a value of 50% | ||
please input as 50.00 | ||||
1 - 1,000 | % | |||
1,001 | - 5,000 | % | ||
5,001 | - 10,000 | % | ||
10,001 - 100,000 | % | |||
100,001 and over | % |
Application for quotation of +securities | 4 / 7 |
Application for quotation of +securities
Issue details
Number of +securities to be quoted | ||||
only | 38,727,835 | |||
Issue currency | Issue price or consideration per +security | |||
AUD - Australian Dollar | AUD 0.18000000 | |||
Any other information the entity wishes to provide about the +securities to be quoted | ||||
Subject to rounding | ||||
use | ASX +security code and description | |||
ATXO : OPTION EXPIRING 31-DEC-2023 | ||||
personal | Issue date | |||
14/12/2021 | ||||
Distribution Schedule | ||||
Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - | ||||
including the number of recipients and the total percentage of the new +securities held by the recipients in each | ||||
category. |
Total percentage of +securities held | ||||
Number of +securities held | Number of holders | For example, to enter a value of 50% | ||
please input as 50.00 | ||||
1 - 1,000 | % | |||
1,001 | - 5,000 | % | ||
For | 5,001 | - 10,000 | % | |
10,001 - 100,000 | % | |||
100,001 and over | % |
Application for quotation of +securities | 5 / 7 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Amplia Therapeutics Ltd. published this content on 19 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 December 2021 21:49:02 UTC.